BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer

Lung Cancer · Published 2026-07-30 · DOI 10.1016/j.lungcan.2026.109556

Authors (10)

Kai Wang, Chao Yi, Xiong Ning, Dalin Xiong, Song Wang, Xiaoying Wu, Hua Bao, Yuan Jiang, Hongyu Deng, Faqing Tang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Wang, K., Yi, C., Ning, X., et al. (2026). BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer. Lung Cancer. https://doi.org/10.1016/j.lungcan.2026.109556

Related articles

• Epiproteomic profiling identifies histone H4 hyperacetylation as a prognostic marker in pleural mesothelioma · Lung Cancer · 2026 · Same journal
• Neoadjuvant and perioperative chemo-immunotherapy in early-stage non-small cell lung cancer: international expert panel meeting by AIOT · Lung Cancer · 2026 · Same journal
• Real-world burden of cardiovascular events following immune checkpoint inhibitor therapy: impact on mortality and treatment resumption in 29,503 patients · Lung Cancer · 2026 · Same journal
• Biology, detection, and management of incidental pulmonary nodules: the emerging role of targeted treatments. A review of the current literature and future perspectives · Lung Cancer · 2026 · Same journal
• Efficacy and safety of immune checkpoint inhibitors in lung cancer patients with hepatitis B surface antigen positivity: a real-world cohort study · Lung Cancer · 2026 · Same journal
• Time-dependent bias in local consolidative therapy for EGFR-mutant metastatic non-small cell lung cancer · Lung Cancer · 2026 · Same journal
• Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy · Lung Cancer · 2026 · Same journal
• CT surveillance, patterns of recurrence and eligibility for salvage therapy after curative intent treatment for unresectable stage III non small cell lung cancer · Lung Cancer · 2026 · Same journal
• First-line treatment for unresectable pulmonary lymphoepithelial carcinoma: A real-world comparison of platinum-based doublet chemotherapy with or without PD-1 inhibitors · Lung Cancer · 2026 · Same journal
• Development and validation of a risk-stratification model for individualized management of leptomeningeal metastases in EGFR- mutant NSCLC (LM-Index) · Lung Cancer · 2026 · Same journal